1,080 material Form 8-K filings that 839 companies we cover made with the SEC in May 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Five Below raised its first-quarter fiscal 2025 guidance on May 2, 2025, expecting net sales of about $967 million and diluted EPS of $0.69 to $0.71, both above prior ranges. Co-founder and Executive Chair Tom Vellios will not stand for re-election at the June 12, 2025 annual meeting and will move to an advisory role through the end of 2025, while director Mike Devine is expected to become non-executive Chair.
Q1 net sales now expected at about $967 million, up from prior guidance of $905 million to $925 million
Q1 diluted EPS now expected at $0.69 to $0.71, up from $0.44 to $0.55; adjusted EPS $0.82 to $0.84, up from $0.50 to $0.61
Comparable sales now expected to rise about 6.7%, versus prior guidance of flat to 2% growth
Vellios's Executive Chair role ends at the June 12, 2025 annual meeting; Mike Devine is expected to be appointed non-executive Chair if re-elected
The Cigna Group reported first quarter 2025 results, with total revenues up 14% to $65.5 billion and shareholders' net income of $1.3 billion, or $4.85 per share, compared with a net loss a year earlier. The company raised its full-year 2025 adjusted income from operations outlook to at least $29.60 per share, up $0.10, which supports earnings expectations for shareholders.
Total revenues rose 14% to $65.5 billion; shareholders' net income was $1.3 billion, or $4.85 per share, versus a $0.3 billion loss ($0.97 per share) in Q1 2024.
Adjusted income from operations was $1.8 billion, or $6.74 per share, compared with $6.47 per share in Q1 2024.
Cigna Healthcare adjusted pre-tax income fell 4% to $1.3 billion, with the medical care ratio rising to 82.2% from 79.9%.
The company completed the sale of its Medicare businesses to HCSC on March 19, 2025, and repurchased 8.2 million shares for about $2.6 billion year to date through May 1, 2025.
BrightSpring reported first quarter 2025 results on May 2, 2025, with net revenue of $2,878 million, up 25.9%, and net income from continuing operations of $9.2 million, compared with a loss of $56.0 million a year earlier. The company raised its full-year 2025 revenue guidance to $12,000 million to $12,500 million and Adjusted EBITDA guidance to $570 million to $585 million, and said the planned sale of its Community Living business to Sevita remains on track this year.
Net revenue of $2,878 million, up 25.9% from $2,286 million in Q1 2024
Net income from continuing operations of $9.2 million, versus a net loss from continuing operations of $56.0 million in Q1 2024
Adjusted EBITDA of $131 million, up 28.2% from $102 million
2025 guidance raised: revenue of $12,000 million to $12,500 million; Adjusted EBITDA of $570 million to $585 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.